Tresivac

Description

TRESIVAC® (Measles, Mumps and Rubella Vaccine (Live) I.P.) is a freeze-dried vaccine prepared from live attenuated strains of measles, mumps and rubella propagated on human diploid cell culture. TRESIVAC is indicated for active immunization in children of 12 months to 10 years of age against Measles, Mumps and Rubella infections simultaneously.

Immunization guideline:

MMR vaccine is recommended for all children at 12 months of age and again at 4-6 years of age unless there is a genuine contraindication.

0.5 ml dose of vaccine  should be administered by deep subcutaneous injection into the anterolateral aspect of upper thigh in toddlers and upper arm in older children.

Additional information

vaccine-type

MMR

manufacturer

Serum Institute of India Ltd.

country-of-manufacture

India

pharmaceutical-form

Lyophilized

package-size

1 Dose

route-of-administration

Subcutaneous

preservative

None

Contraindications

Pregnancy, Leukaemia and other malignant diseases, severe febrile diseases, or impairment of CNS, history of known hypersensitivity to egg protein, anaphylactic reactions to neomycin.Women should avoid becoming pregnant for 28 days after vaccination with measles or mumps vaccines, MMR or MR vaccine or other rubella vaccines.